OCGN logo Ocugen : OCGN

OCGN

Stock Data

$1.80

Change up

$0.07 (4.05%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Ocugen Inc is a pioneering biopharmaceutical company dedicated to developing innovative gene therapies aimed at curing blindness caused by a variety of diseases. With a focus on genetic eye diseases such as retinitis pigmentosa and leber congenital amaurosis, Ocugen's leading product, OCU400, represents a significant advancement in retinal therapy. The company also explores treatments for age-related macular degeneration and diabetic eye diseases through its diverse pipeline, including OCU410 and OCU200. Ocugen's commitment to eye health extends through strategic partnerships, enhancing its research and development capabilities. Headquartered in Malvern, Pennsylvania, Ocugen strives to bring new hope to individuals suffering from vision loss.

All Ocugen Articles

15 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.